Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Metoprolol
Drug ID BADD_D01445
Description Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative.[T274] To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US.[A175162] Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.[L5527]
Indications and Usage Metoprolol is indicated for the treatment of angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension.[A175141] Some off-label uses of metoprolol include supraventricular tachycardia and thyroid storm.[A175141] All the indications of metoprolol are part of cardiovascular diseases. These conditions correspond to a number of diseases that involve the function of the heart and blood vessels. The underlying causes of these conditions are variable and can be due to genetic disposition, lifestyle decisions such as smoking, obesity, diet, and lack of exercise, and comorbidity with other conditions such as diabetes. The cardiovascular diseases are the leading cause of death on a global scale.[L5533]
Marketing Status approved; investigational
ATC Code C07AB02
DrugBank ID DB00264
KEGG ID D02358
MeSH ID D008790
PubChem ID 4171
TTD Drug ID D0I2MK
NDC Product Code 70518-3506; 46708-292; 62207-970; 62332-113; 46708-290; 0615-8422; 0615-8423; 46708-291; 62332-114; 62332-112; 71205-003; 0615-8421; 65977-0117
UNII GEB06NHM23
Synonyms Metoprolol | Toprol | Betaloc | Betaloc-Astra | Betaloc Astra | Betalok | CGP-2175 | CGP 2175 | CGP2175 | H 93-26 | H 93 26 | H 9326 | Metoprolol Tartrate | Seloken | Spesicor | Spesikor | Metoprolol Succinate | Metoprolol CR-XL | Metoprolol CR XL | Toprol-XL | Toprol XL | Beloc-Duriles | Beloc Duriles | Lopressor
Chemical Information
Molecular Formula C15H25NO3
CAS Registry Number 51384-51-1
SMILES CC(C)NCC(COC1=CC=C(C=C1)CCOC)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Withdrawal syndrome19.07.06.023; 08.06.02.012--Not Available
Yellow skin09.01.01.009; 08.01.03.046; 23.03.03.0420.000007%Not Available
Mental status changes19.07.01.0010.000043%Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.030--Not Available
Cardiotoxicity02.11.01.009; 12.03.01.0070.000057%Not Available
Coronary artery dissection12.02.01.035; 24.02.02.001; 02.02.01.0040.000007%Not Available
Hypoacusis04.02.01.006--
Brain oedema17.07.02.003; 12.01.10.0100.000030%
Emotional distress19.04.02.008--Not Available
Sudden cardiac death08.04.01.008; 02.03.04.0160.000010%Not Available
Precancerous skin lesion23.01.06.0040.000010%Not Available
General physical health deterioration08.01.03.0180.000080%Not Available
Tachyarrhythmia02.03.02.0080.000010%Not Available
Left ventricular dysfunction02.04.02.0110.000007%
Bradyarrhythmia02.03.02.0150.000030%Not Available
Left ventricular hypertrophy02.04.02.0140.000007%Not Available
Ventricular hypokinesia02.04.02.0130.000010%Not Available
Lupus-like syndrome23.03.02.004; 15.06.02.004; 10.04.03.0030.000007%Not Available
Blood pressure inadequately controlled24.06.01.0070.000093%Not Available
Central nervous system lesion17.02.10.011--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000017%Not Available
Cytokine release syndrome10.02.01.0100.000010%
Haemodynamic instability24.03.02.0060.000047%Not Available
Eye pruritus06.04.05.006--Not Available
Eosinophilic pneumonia acute01.02.04.004; 22.01.01.0080.000007%Not Available
Cardiac flutter02.03.02.0120.000023%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.0010.000010%Not Available
Affect lability19.04.01.001--Not Available
Transaminases increased13.03.04.036--Not Available
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene